LeadershipNew leadership appointment with Vinay Shah as the company's CFO brings over 25 years of experience in the pharmaceutical, biopharmaceutical, and healthcare sectors, specializing in financial strategy.

Regulatory ApprovalAdial announced positive top-line results from its pharmacokinetics (PK) study of AD04, which confirmed the relative bioavailability to marketed ondansetron and no food effects.

Regulatory FeedbackAdial announced the positive feedback it received from US and EU regulators around its AD04 program, following regulatory meetings.

Bears Say

Financial OverhangAdditional capital is required to advance this program and as such, a Hold rating is maintained as the company works to resolve its financial overhang.

Financial PerformanceAdial filed its 10-Q, reporting 3Q24 results with a net loss of ($2.2M) and ended the period with $5.2M in cash on the balance sheet.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

23.12%

Insiders

0.92% Mutual Funds

1.19% Other Institutional Investors

74.58% Public Companies and Individual Investors

Detailed Ownership Overview >

ADIL FAQ

What was Adial Pharmaceuticals Inc’s price range in the past 12 months?

Adial Pharmaceuticals Inc lowest stock price was $0.38 and its highest was $3.00 in the past 12 months.

What is Adial Pharmaceuticals Inc’s market cap?

Adial Pharmaceuticals Inc’s market cap is $3.95M.

When is Adial Pharmaceuticals Inc’s upcoming earnings report date?

Adial Pharmaceuticals Inc’s upcoming earnings report date is Aug 13, 2025 which is in 59 days.

How were Adial Pharmaceuticals Inc’s earnings last quarter?

Adial Pharmaceuticals Inc released its earnings results on May 15, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.495 by $0.155.

Is Adial Pharmaceuticals Inc overvalued?

According to Wall Street analysts Adial Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Adial Pharmaceuticals Inc pay dividends?

Adial Pharmaceuticals Inc does not currently pay dividends.

What is Adial Pharmaceuticals Inc’s EPS estimate?

Adial Pharmaceuticals Inc’s EPS estimate is -0.25.

How many shares outstanding does Adial Pharmaceuticals Inc have?

Adial Pharmaceuticals Inc has 8,719,695 shares outstanding.

What happened to Adial Pharmaceuticals Inc’s price movement after its last earnings report?

Adial Pharmaceuticals Inc reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.495. Following the earnings report the stock price went up 1.538%.

Which hedge fund is a major shareholder of Adial Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in ADIL

Company Description

Adial Pharmaceuticals Inc

Adial Pharmaceuticals (ADIL) is a clinical-stage biopharmaceutical company specializing in developing therapeutic treatments for addiction and related disorders. Headquartered in the United States, the company's core product focuses on a genetically targeted medication designed to combat alcohol use disorder (AUD). Adial leverages its expertise in genetics and addiction treatment to develop innovative solutions aimed at improving patient outcomes in the field of addiction medicine.